Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)
about
Efavirenz and the CNS: what we already know and questions that need to be answeredAssociation between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.HIV-associated neurocognitive disorder.Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.Neurological and psychiatric adverse effects of antiretroviral drugs.Efavirenz modulation of sleep spindles and sleep spectral profile.Neuropsychiatric Effects of HIV Antiviral Medications.Cognitive impairment in patients with AIDS - prevalence and severity.Depression in HIV infected patients: a review.CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.PharmGKB summary: Efavirenz pathway, pharmacokineticsAbsence seizures associated with efavirenz initiationCase report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation.Longitudinal study of emerging mental health concerns in youth perinatally infected with HIV and peer comparisonsLong-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patientsAssessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange programEvaluating sleep and cognition in HIVPatient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review.Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.HIV and neurocognitive dysfunction.Neuronal toxicity of efavirenz: a systematic review.Review of the impact of NNRTI-based HIV treatment regimens on patient-reported disease burden.HIV-associated Neurocognitive Disorders and Antiretroviral Therapy: Current Concepts and Controversies.A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.Depression and anxiety were low amongst virally suppressed, long-term treated HIV-infected individuals enrolled in a public sector antiretroviral program in Thailand.Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients.Use of Western Neuropsychological Test Battery in Detecting HIV-Associated Neurocognitive Disorders (HAND) in Zambia.Prevalence and Risk Factors of Sleep Disturbance in a Large HIV-Infected Adult Population.Risk of clinically significant depression in HIV-infected patients: effect of antiretroviral drugs.Incidence of neuropsychiatric side effects of efavirenz in HIV-positive treatment-naïve patients in public-sector clinics in the Eastern Cape.High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily
P2860
Q28085028-196D205F-FAE7-4AC8-B1C7-795F9059F8CFQ30834094-20E1901B-98F6-4075-8E55-47033003FA99Q33413634-1E60A8AB-AAA2-40C8-9A94-449CEF4A639EQ33939729-B81BDF2E-E87D-45E7-AFE3-7C46FC771DA9Q34035045-C2546E92-CD0C-48E0-98AE-FF3FA0EF5938Q34039419-F97578AD-858E-4A30-B053-60D442356F82Q34433247-E8A7158A-412B-455E-89DD-66BD1A6E4A7DQ34537705-59700DE4-D1C0-48CA-A514-33EFCEE7E21DQ35057500-F127D53E-85C9-467B-BF9A-314B51E5C110Q35440924-EE433DAF-3FD4-4F14-817E-B8577FAED809Q35518558-9F700269-23B9-490A-90D7-1328E6C6D335Q35706069-C259D91D-4D6A-45ED-A57F-B7B0340360CBQ35752638-14A9702D-A017-4F65-A6FE-EA4546D78A57Q35910664-A41CF749-13BE-4F50-A6A5-54B81DBA5131Q36462000-C559D79B-07A6-4ECC-BF91-52C0BBF272FBQ36664960-5C31867F-B2D8-45E8-8C06-4121BB582FC7Q36853897-B922638A-DB9A-44AC-BBCF-28D6D3482A5CQ37294737-37D69796-E7FF-45B2-BDC1-FBC623FD0E9DQ37366279-B5EC02DD-F71D-4282-A60C-21DCC5D17848Q38083294-3DD7572E-E79A-4AF8-B0D4-BFC203F049A8Q38122104-86F69BB5-3BE8-4006-9C34-666C67A999EBQ38124394-E5117629-3E3D-4848-94DE-7432E8CF42D8Q38151171-4EE433D6-9A3F-4DC9-A541-D1DE5B0B59F4Q38444808-71BC2C29-8AC2-4143-8587-6EEBF817A3E5Q38743628-829915B5-54EC-4394-8CF8-513B7AAB511DQ40523281-1DB3D24D-B4B2-4291-92F6-43945114EA7FQ40531475-81BF693C-A7FC-4696-BE6E-D45C909470BDQ40640105-7B8A156B-AAA9-4193-8D10-12FFB2CAF102Q41053513-86FEFC46-65DF-4A8C-8401-B81FBA508EAAQ42241221-044955DA-4EE0-4B3E-9F92-1591DFD81D04Q53759304-F0A3F9C2-BE43-4C6A-AAD0-730EA2417B09Q56910903-EFD2A983-AA95-40F8-A158-3C8D75E094BE
P2860
Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Long-term impact of efavirenz ...... ected individuals (ACTG 5097s)
@ast
Long-term impact of efavirenz ...... ected individuals (ACTG 5097s)
@en
Long-term impact of efavirenz ...... ms in HIV-infected individuals
@nl
type
label
Long-term impact of efavirenz ...... ected individuals (ACTG 5097s)
@ast
Long-term impact of efavirenz ...... ected individuals (ACTG 5097s)
@en
Long-term impact of efavirenz ...... ms in HIV-infected individuals
@nl
prefLabel
Long-term impact of efavirenz ...... ected individuals (ACTG 5097s)
@ast
Long-term impact of efavirenz ...... ected individuals (ACTG 5097s)
@en
Long-term impact of efavirenz ...... ms in HIV-infected individuals
@nl
P2093
P2860
P356
P1433
P1476
Long-term impact of efavirenz ...... ected individuals (ACTG 5097s)
@en
P2093
A5097s Study Team
David B Clifford
Edward P Acosta
Heather Ribaudo
Roy M Gulick
Scott Evans
Yijun Yang
P2860
P304
P356
10.1310/HCT1006-343
P577
2009-11-01T00:00:00Z